Get the Stockscreener App
0.2842
1.00%
0.0028
Bioaffinity Technologies Inc stock is traded at $0.2842, with a volume of 343.84K.
It is up +1.00% in the last 24 hours and up +34.76% over the past month.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
See More
Previous Close:
$0.2814
Open:
$0.2793
24h Volume:
343.84K
Relative Volume:
0.03
Market Cap:
$7.83M
Revenue:
$9.37M
Net Income/Loss:
$-8.45M
P/E Ratio:
-0.3509
EPS:
-0.81
Net Cash Flow:
$-7.27M
1W Performance:
+1.50%
1M Performance:
+34.76%
6M Performance:
-72.67%
1Y Performance:
-87.48%
1-Day Range:
$0.2698
$0.289
1-Week Range:
$0.26
$0.3156
52-Week Range:
$0.1639
$2.9893
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.2842 | 7.83M | 9.37M | -8.45M | -7.27M | -0.81 |
|
TMO
Thermo Fisher Scientific Inc
|
401.90 | 152.06B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
196.02 | 135.91B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
524.91 | 41.29B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.80 | 31.79B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
152.32 | 24.28B | 15.50B | 1.33B | 2.16B | 7.34 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
BIAFbioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 - mx.advfn.com
Case Study: bioAffinity Technologies’ Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence - mx.advfn.com
bioAffinity Technologies Works With Cardinal Health™ OptiFreight® Logistics to Help Meet Demand for CyPath® Lung - Yahoo Finance
Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Grows By 58.8% - Defense World
bioAffinity Receives Nasdaq Non-Compliance Notice - TipRanks
BioAffinity Technologies Secures Patent for Novel Cancer Therapy Targeting CD320 and LRP2 Receptors - Insider Monkey
BioAffinity Technologies Announces New U.S. Patent For Novel Broad Spectrum Cancer Therapeutics - marketscreener.com
BIAF Gains New Patent for Innovative Cancer Treatment Method | B - GuruFocus
Revolutionary Cancer Treatment Patent: bioAffinity's New Therapy Kills Cancer Cells While Sparing Healthy Ones - Stock Titan
bioAffinity Technologies Enters Sales Agreement with WallachBeth - TipRanks
bioAffinity Technologies (NASDAQ:BIAF) Trading Down 3.1% – What’s Next? - Defense World
BIAF Stock Rises Post Q1 Earnings Despite Revenue Decline - MSN
bioAffinity Technologies names new chief medical officer By Investing.com - Investing.com South Africa
bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer - citybiz
BioAffinity Technologies (BIAF) Appoints Gordon Downie as Chief Medical Officer | BIAF Stock News - GuruFocus
bioAffinity Technologies names new chief medical officer - Investing.com Australia
From Olympic Bronze to Cancer Breakthrough: bioAffinity Names Elite Physician as New CMO - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
bioAffinity Technologies Sets 2025 Annual Meeting Date - TipRanks
bioAffinity Technologies Reports Strong Q1 2025 Growth - MSN
bioAffinity Technologies, Inc. SEC 10-Q Report - TradingView
bioAffinity Technologies Reports First Quarter 2025 Results - Business Wire
bioAffinity Technologies Completes $3.2M Public Offering - TipRanks
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering - The Malaysian Reserve
Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer - Stock Titan
bioAffinity announces $3.25 million securities offering By Investing.com - Investing.com Nigeria
bioAffinity Technologies completes $3.25 million offering By Investing.com - Investing.com South Africa
BioAffinity Technologies Closes $3.25 Million Offering - marketscreener.com
bioAffinity Technologies (BIAF) Completes $3.25M Securities Offering | BIAF Stock News - GuruFocus
bioAffinity Technologies completes $3.25 million offering - Investing.com
bioAffinity Technologies Announces Closing of $3.25 Million Offering - Bluefield Daily Telegraph
bioAffinity Technologies Boosts Data Acquisition for CyPath Lung Test - Medical Product Outsourcing
BioAffinity Technologies announces pricing of $3.25M offering - Yahoo Finance
Crude Oil Rises Sharply; US Trade Deficit Widens In March - Benzinga
WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering - Eastern Progress
The Zacks Analyst Blog Highlights Alphabet, Berkshire Hathaway, Visa and bioAffinity Technologies - NewsBreak: Local News & Alerts
Cancer Detection Biotech bioAffinity Secures Fresh $3.25M Funding: Key Details of Latest Stock Offering - Stock Titan
bioAffinity announces $3.25 million securities offering - Investing.com Australia
Dow Falls Over 250 Points; Marriott Posts Upbeat Earnings - Benzinga
bioAffinity Technologies Announces Pricing of $3.25 Million Offering - Business Wire
Top Stock Reports for Alphabet, Berkshire Hathaway & Visa - Yahoo Finance
Japanese startup ‘Craif’ raises US$22M to bring urine cancer biopsy to the U.S. - Mugglehead Magazine
bioAffinity Technologies (NASDAQ:BIAF) Shares Up 2.7% – Still a Buy? - Defense World
bioAffinity Technologies streamlines lung cancer detection test By Investing.com - Investing.com Canada
bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost - BioSpace
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):